Hong Kong Stock Movement | Kelun-Botai Biotech (06990.HK) rose over 4% in the morning as the clinical trial application for the new dual-delivery ADC drug SKB565 was approved.

Zhuhai Finance APP has learned that Kelun-Botai Biotechnology (06990.HK) rose over 4% in the morning session, and as of the time of writing, it is up 3.8%, priced at HKD 510.5, with a trading volume of HKD 95.924 million.